XLock Biosciences, Inc.

[XLock Biosciences, Inc. @LlcXlock]

Dr. Clarke and Dr. Volkman, our CEO and CSO, will be presenting our poster "XL106: A Novel CCL20 Locked Dimer for the Treatment of TH-17 Driven Ophthalmic Diseases" at the #ARVO2026 meeting in Denver, CO. Stop by Session 428 on May 6 between 10:15 and 12:00 pm to hear more.

[Brian Volkman @bvolkie]

There's a first time for everything...check out my lab's first protein structures solved by cryoEM (also the first cryoEM structures ever solved on the @MedicalCollege Glacios), our first @biorxivpreprint deposition, first inactive ACKR3 structure...

https://t.co/TNRjChQbU1

[XLock Biosciences, Inc. @LlcXlock]

Our CMO, Dr. Samuel Hwang is Professor and Chair of Dermatology at UC Davis and has over 25 years of experience as a physician-scientist in skin immunology. Supported by NIH as well as the National Psoriasis Foundation, he is recognized for his work in psoriasis pathogenesis.

[XLock Biosciences, Inc. @LlcXlock]

❄️Happy Holidays from XLock Biosciences, Inc ❄️

As we reflect on the year behind us, we’re excited for what’s ahead. Thank you to everyone who continues to support innovation and progress. Here’s to a healthy, impactful New Year.

[XLock Biosciences, Inc. @LlcXlock]

Chief Translational Science Officer, Mike Dwinell, PhD. is a professor of Microbiology & Immunology and Surgery and director of the Center for Immunology. His NIH funded research has centered on the pathophysiologic mechanisms of inflammation, tumor progression, and metastasis.

[XLock Biosciences, Inc. @LlcXlock]

CSO, Brian Volkman PhD, MCW Professor of Biochemistry is recognized for his contributions in the fields of structural genomics, protein dynamics and precision medicine. Engineered chemokines developed in his lab have been licensed by multiple companies for therapeutic development

[XLock Biosciences, Inc. @LlcXlock]

CEO Dr. Wm Clarke is a physician and molecular pharmacologist; has over 30 years of experience as
Dir. of Biological Sciences at GlaxoWellcome, Global Head of R&D at Amersham, CEO of Cellectar and recently, Dir. of the Drug, Device and Diagnostic accelerator at Boston Children’s.

[XLock Biosciences, Inc. @LlcXlock]

Our President Francis Peterson, PhD, is a Professor of Biochemistry at the Medical College of Wisconsin, with over 20 years of research experience in cytokine and chemokine protein design and structure. Work producing over 100 publications and 70 protein structures.

[XLock Biosciences, Inc. @LlcXlock]

The chemokine network is incredibly complex. Our XL106 molecule leverages the monogamous relationship between CCL20 and CCR6 to access high-value precision therapeutic pathways.

[XLock Biosciences, Inc. @LlcXlock]

So, what is a chemokine?
Chemokines are small signaling proteins that guide immune cell migration. Binding to chemokine receptors, they orchestrate immunity, inflammation, and tissue repair.  XLock's team is working to unlock the chemokine potential to treat disease.

[XLock Biosciences, Inc. @LlcXlock]

At the European Chemokine and Cell Migration Conference in Copenhagen, CSO Dr. Brian Volkman presented findings from his latest paper in a talk titled:

“Encoding and Decoding Selectivity and Promiscuity in the Human Chemokine-GPCR Interaction Network.”

https://t.co/4UGfMecQ8B

[XLock Biosciences, Inc. @LlcXlock]

XLock Co-Founder and Chief Scientific Officer Dr. Brian Volkman participated in the opening panel of the 2025 Healthcare Innovation Pitch at Summerfest Tech. Alongside other fellow start-up founders, Dr. Volkman shared insights learned in the founding their companies.

[XLock Biosciences, Inc. @LlcXlock]

XLock is developing therapies that precisely target chemokine interactions, addressing critical unmet needs in inflammatory and oncology diseases.

Our XL100 series focuses on the monogamous CCR6-CCL20 interaction.

[XLock Biosciences, Inc. @LlcXlock]

Our President, Dr. Francis Peterson and our CSO, Dr. Brian Volkman, recently co-authored a paper featured on the cover of Cell.
https://t.co/8uhtSaCIx6

[XLock Biosciences, Inc. @LlcXlock]

XLock Biosciences celebrates all fathers this weekend!

[XLock Biosciences, Inc. @LlcXlock]

XLock Chief Translational Science Officer, Mike Dwinell, PhD. presided over the MCW Center for Immunology 15th Annual Scientific Retreat on June 4. Dr. Dwinell is the founding Director of the C4I. The retreat is an annual event to share current immunology research and knowledge.

[XLock Biosciences, Inc. @LlcXlock]

XLock Biosciences remembers all who fought and gave the ultimate sacrifice for our freedom.

[XLock Biosciences, Inc. @LlcXlock]

WHY CHEMOKINE BIOLOGY?

XLock is pioneering a new way forward by designing molecules that selectively modulate chemokine activity to address complex disease mechanisms in immunology and oncology.

View our science here: https://t.co/iJU8tLMsB0